Disease relevance of Herpesviridae Infections

• Vidarabine therapy for severe herpesvirus infections. An unusual syndrome of chronic varicella and transient immunologic deficiency [1].
• To define immune mechanisms that regulate chronic and latent herpesvirus infection, we analyzed the role of interferon gamma (IFN-gamma) during murine cytomegalovirus (MCMV) infection [2].
• They were selected either because they are already approved for clinical use in the treatment of herpesvirus infections (acyclovir, valaciclovir, penciclovir, famciclovir, ganciclovir, brivudin, foscarnet and cidofovir) or have demonstrated marked activity against herpesviruses (lobucavir, H2G, A-5021, D/L-cyclohexenyl G and S2242) [3].
• In vitro activities of methylenecyclopropane analogues of nucleosides and their phosphoralaninate prodrugs against cytomegalovirus and other herpesvirus infections [4].
• The famciclovir population consisted of 816 herpes zoster patients (four trials), 409 patients with acute genital herpesvirus infections (seven trials), and 382 patients from two genital herpes suppression studies [5].

High impact information on Herpesviridae Infections

• Visceral herpesvirus infections in leukemic patients receiving cytarabine [6].
• Autopsy evidence of herpesvirus infection was found in visceral organs of four leukemic patients who had received large doses of cytarabine (cytosine arabinoside; Ara-C) shortly before their death [6].
• The use of 2-deoxy-D-glucose provides a simple and unique approach to the treatment of genital herpesvirus infections [7].
• Antibodies against MnSOD belong to the immunoglobulin class M. They are not detectable in sera of patients with other herpesvirus infections [8].
• However, whether this CCR5 gene variation modifies immunity to common herpesvirus infections is unknown [9].

Chemical compound and disease context of Herpesviridae Infections

• Six patients with severe herpesvirus infections were successfully treated with vidarabine [1].
• Parenteral acyclovir therapy for herpesvirus infections in man [10].
• Acyclovir, penciclovir, and their prodrugs have been widely used during the past two decades for the treatment of herpesvirus infections [11].
• Patients receiving single-agent fludarabine had more major infections and herpesvirus infections compared with chlorambucil-treated patients [12].
• Phase I evaluation of 2'-fluoro-5-iodo-1-beta-D-arabinofuranosylcytosine in immunosuppressed patients with herpesvirus infection [13].

Biological context of Herpesviridae Infections

• Foscarnet is widely used for the treatment of acyclovir-resistant herpesvirus infections, and foscarnet-resistant herpesvirus infections are a serious concern in immunocompromised patients [14].
• Heterotypic antibody responses were not seen with sera from other human herpesvirus infections [15].
• OBJECTIVE: To discuss the clinical pharmacology, antiviral activity, clinical efficacy, and other therapeutic issues associated with valacyclovir use for the treatment of herpesvirus infections [16].
• OBJECTIVE: To discuss the antiviral activity, pharmacokinetics, clinical efficacy, and adverse effect profile of famciclovir, the oral prodrug of penciclovir (PCV), and to compare these features of famciclovir with those of acyclovir in the treatment of herpesvirus infections [17].
• Caprine herpesvirus infection in Switzerland: some aspects of its pathogenicity [18].

Anatomical context of Herpesviridae Infections

• We conclude that (i) M phi activation is a prominent part of inflammatory responses to herpesvirus infection and (ii) IFN gamma and TNF alpha play a critical role in both virus-induced M phi activation and control of herpesvirus growth independent of T and B cells [19].
• Central nervous system herpesvirus infection in systemic lupus erythematosus: diagnosis by endoretinal biopsy [20].
• Fetuses aborted as a result of caprine herpesvirus infection have tissue necrosis and intranuclear inclusion bodies in multiple organs [21].
• Inclusion body disease of falcons (Herpesvirus infection) in an American kestrel [22].
• The data suggest that cyclosporine treatment inhibits the activation of suppressor cells and depression of cellular immune function that have been associated with herpesvirus infections in renal transplant recipients undergoing conventional immunotherapy [23].

Gene context of Herpesviridae Infections

• However to date the effects of acute herpesvirus infection on metabolism of APP in human neuronal-type cells have not been investigated [24].
• Overall, the results suggest that the dipeptide prodrugs of ACV have a high affinity toward the intestinal oligopeptide transporter hPEPT1 and therefore seem to be promising candidates in the treatment of ocular and oral herpesvirus infections, because cornea and intestinal epithelia seem to express the oligopeptide transporters [25].
• Herpesvirus infection of ICAM-1-deficient mice [26].
• Although the precise details of IRF3 activation and interferon production in response to herpesvirus infection are still being elucidated, viral proteins that block components of the interferon pathway, particularly IRF3, have been identified and characterized [27].
• Polymerase chain reaction as a diagnostic adjunct in herpesvirus infections of the nervous system [28].

Analytical, diagnostic and therapeutic context of Herpesviridae Infections

• Glucose analogues in the chemotherapy of herpesvirus infections [29].
• BACKGROUND: Mycophenolate mofetil (MMF) has been approved as an immunosuppressive agent in kidney transplant recipients and may thus be used concomitantly with antiherpetic agents, the latter for the treatment of intercurrent herpesvirus infections [30].
• Thus, cyclaradine or its 5'-methoxyacetic acid ester may possess some advantage over vidarabine in the treatment of severe herpesvirus infections and should therefore be considered for clinical trials in humans [31].
• This article provides an overview of pulmonary herpesvirus infections that occur after hematopoietic cell transplantation, with an emphasis on new developments in epidemiology, diagnosis, prophylaxis, and treatment [32].

References